Literature DB >> 6182799

Fluorouracil for the treatment of massive periretinal proliferation.

M S Blumenkranz, A Ophir, A J Claflin, A Hajek.   

Abstract

A single intravitreal injection of fluorouracil was effective in the treatment of an experimental model of massive periretinal proliferation. When given with an intravitreal injection of 250,000 heterologous fibroblasts, fluorouracil decreased the rate of tractional retinal detachment from 36.8% in controls (seven of 19 eyes) to 5.2% in treated animals (one of 19 eyes) at one week, and from 73.6% in controls (14 of 19 eyes) to 31.5% in treated animals (six of 19 eyes) after four weeks (P less than .05). Intraocular neovascularization was reduced from 52.6% in controls (ten of 19 eyes) to 5.2% in treated animals (one of 19 eyes) after one week and 36.8% in controls (seven of 19 eyes) to 5.2% in treated animals (one of 19 eyes) after four weeks. When supplemented by repeated 10-mg subconjunctival injections of fluorouracil, or in combination with intravitreally administered indomethacin, this effect appeared to be enhanced. Intravitreal and subconjunctival injections of fluorouracil were well tolerated and may prove to be of significant value in the treatment of human disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182799     DOI: 10.1016/0002-9394(82)90239-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  40 in total

1.  Detection of eicosanoids in epiretinal membranes of patients suffering from proliferative vitreoretinal diseases.

Authors:  A J Augustin; F H Grus; F Koch; M Spitznas
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

2.  Postoperative subconjunctival 5-fluorouracil in the management of recurring pterygium.

Authors:  Anupama Pherwani; Vipul Vakil; Habibullah Eatamadi; Ravinder Singh; Harminder S Dua
Journal:  Br J Ophthalmol       Date:  2007-03       Impact factor: 4.638

Review 3.  The pars plana incision: experimental studies, pathologic observations, and clinical experience.

Authors:  A E Krieger
Journal:  Trans Am Ophthalmol Soc       Date:  1991

4.  5-fluorouracil and beyond.

Authors:  P T Khaw; I Grierson; R A Hitchings; N S Rice
Journal:  Br J Ophthalmol       Date:  1991-10       Impact factor: 4.638

5.  The use of a liposome-encapsulated 5-fluoroorotate for glaucoma surgery: I. Animal studies.

Authors:  J A Alvarado
Journal:  Trans Am Ophthalmol Soc       Date:  1989

6.  The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR).

Authors:  Khaled Nassar; Julia Lüke; Matthias Lüke; Mahmoud Kamal; Effat Abd El-Nabi; Mahmoud Soliman; Martin Rohrbach; Salvatore Grisanti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-07       Impact factor: 3.117

7.  Effects of single, short-term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy.

Authors:  C H Kon; N L Occleston; A Foss; C Sheridan; G W Aylward; P T Khaw
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

8.  Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study.

Authors:  S Binder; M Bonnet; M Velikay; J P Gerard; U Stolba; A Wedrich; H Hohenberg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

9.  Experimental study on drug therapy of "traction retinal detachment" after posterior penetrating eye injury in the rabbit.

Authors:  W Behrens-Baumann; M Vogel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

10.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.